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ABSTRACT
Pax6 transcription is under the control of two main
promoters (P0 and P1), and these are autoregulated
by Pax6. Additionally, Pax6 expression is under the
control of the TGFb superfamily, although the
precise mechanisms of such regulation are not
understood. The effect of TGFb on Pax6 expression
was studied in the FHL124 lens epithelial cell line
and was found to cause up to a 50% reduction in
Pax6 mRNA levels within 24h. Analysis of luciferase
reporters showed that Pax6 autoregulation of the P1
promoter, and its induction of a synthetic promoter
encoding six paired domain-binding sites, were
significantly repressed by both an activated TGFb
receptor and TGFb ligand stimulation.
Subsequently, a novel Pax6 binding site in P1 was
shown to be necessary for autoregulation, indicat-
ing a direct influence of Pax6 protein on P1. In
transfected cells, and endogenously in FHL124
cells, Pax6 co-immunoprecipitated with Smad3
following TGFb receptor activation, while in GST
pull-down experiments, the MH1 domain of Smad3
was observed binding the RED sub-domain of the
Pax6 paired domain. Finally, in DNA adsorption
assays, activated Smad3 inhibited Pax6 from bind-
ing the consensus paired domain recognition
sequence. We hypothesize that the Pax6 autoregu-
latory loop is targeted for repression by the TGFb/
Smad pathway, and conclude that this involves
diminished paired domain DNA-binding function
resulting from a ligand-dependant interaction
between Pax6 and Smad3.
INTRODUCTION
Pax6 is a member of the paired-type homeobox gene
family, of which there are nine in total (1). A number of
developmental abnormalities are attributable to muta-
tions in Pax6 including Small Eye in mouse, Aniridia in
humans and Eyeless in Drosophila, and overexpression
can cause ectopic eye formation (2). Pax6 encodes a
protein containing a paired domain, paired-type homeo-
domain and a C-terminal transactivation domain. The
paired domain is 128 amino acids in length, and was ﬁrst
described in the Drosophila segmentation genes paired,
gooseberry and gooseberry neuro (3), and is characteristic
of all members of the Pax gene family. The bi-partite
paired domain binds as a monomer to two half sites in
adjacent major grooves in DNA comprising the core
nonpalindromic sequence T{T/C}ACGC (4). The paired-
type homeodomain binds preferentially to DNA as a
dimer to a palindromic sequence comprising two TAAT
half-sites surrounding a conserved central motif (5).
Interestingly, the paired and homeodomains can interact
directly and, based on co-immunoprecipitation studies
with other homeodomain-containing proteins, it has been
suggested that the DNA binding regions of Pax6
should also be viewed as important protein–protein
interaction domains capable of both intramolecular and
intermolecular interactions (6).
Pax6 transcription is under the control of at least two
promoters (P0 and P1). Studies on the quail Pax6
promoters revealed that Pax6 protein is able to bind
multiple sites in both P0 and P1 (7,8). Autoregulation was
suggested based on mouse genetic experiments (9), and
has since been observed with both of the human
promoters (10), as well as several Pax6 enhancer
sequences in mouse (11,12). Additional evidence for
autoregulation comes from studies of Small eye mutant
phenotypes in mice. One particular Small eye mutant
allele, Sey, is the product of a single point mutation, and
results in a protein that is truncated before the homeo-
domain (1). While this is suﬃcient to disrupt Pax6
function, it does not interfere with the detection of Pax6
mRNA by in situ hybridization. During the development
of Sey homozygous mice, Pax6 mRNA is expressed
normally prior to lens speciﬁcation. However, expression
is completely lost throughout the head surface ectoderm
post-speciﬁcation, when it would normally be conﬁned to
the presumptive lens placodes (13). An earlier study has
also suggested the existence of Pax6 autoregulation in the
developing forebrain (14).
The precise co-ordination of upstream signalling
pathways in controlling Pax6 expression is not clear,
although several pathways have been implicated including
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TGFb superfamily (18–22). TGFbs control a broad range
of normal biological activities including cell growth, bone
development, cell migration, diﬀerentiation and apoptosis
(23,24). TGFbs signal through serine/threonine kinase
receptors that phosphorylate TGFb/activin/BMP path-
way restricted R-Smads (Smads 1, 2, 3, 5, 8). Receptors
for activin/TGFb can activate Smad2, Smad3 and Smad8,
and receptors for BMPs activate Smad1 and Smad5.
In all cases, the phosphorylated R-Smads then associate
with a common-mediator or co-Smad (Smad4). These
heteromeric complexes are translocated to the nucleus,
where they regulate gene transcription by either associa-
tion with DNA-binding proteins or direct binding to
promoter sequences in target genes.
There is some circumstantial evidence in the literature
for functional connections between TGFbs and Pax6,
particularly in the context of eye and neural development.
In BMP7-deﬁcient mice, Pax6 expression disappears just
prior to the time when the lens placode should appear, and
this correlates with defects in eye development (19)
suggesting that BMP7 functions upstream of Pax6 in
controlling lens formation. In addition, studies involving
the manipulation of BMP signalling in the chick neural
tube have shown that BMP regulates the expression
boundary of Pax6, and that this is essential for
the generation of deﬁned neural cell populations (19).
Perhaps the most compelling evidence for a link is
demonstrated by the treatment of isolated chick neural
plate with Activin A resulting in complete loss of Pax6
expression in the neural tube and impeded motor neuron
diﬀerentiation (18). More recent studies have also shown
that Smad1
þ/  mice exhibit increased neural Pax6
expression (21).
In this study, we show for the ﬁrst time that Pax6
expression can be directly controlled by the TGFb/Smad
signalling system, and also deﬁne the molecular basis of
this novel regulatory mechanism. Pax6-stimulated activity
of the Pax6 promoter is repressed by TGFb signalling.
In GST pull-down experiments, Pax6 interacts with Smad
1, 3, 4 and 5, but not Smad2, and the MH1 domain of
Smad3 binds to the paired domain of Pax6 releasing
it from its own promoter-binding site. Taken together, our
data suggest a model in which TGFb receptor activation
represses Pax6 promoter activity by releasing Pax6 from
autoregulating its own promoter.
MATERIALS AND METHODS
Cell cultureand transfections
FHL124 cells were cultured in Eagles Minimal Essential
Medium (Invitrogen) supplemented with penicillin, strep-
tomycin and 5% (v/v) heat-inactivated fetal bovine serum
(Gibco) as described (25). HEK-293 cells were maintained
in Dulbecco’s Modiﬁed Eagles Medium (Invitrogen)
containing 4500mg/ml glucose and supplemented with
penicillin, streptomycin and 10% (v/v) heat-inactivated
fetal bovine serum (Sigma). HEK-293 cells were tran-
siently transfected by calcium phosphate precipitation of
DNA. The quantities of transfected DNA were kept
constant by adding an appropriate amount of empty
vector pCMV1.
Quantitative RT-PCR
FHL 124 cells were seeded on to 35mm dishes at 30,000
cells in 400ml of 5%FCS-EMEM (Gibco, Invitrogen Ltd,
Paisley, UK) and were maintained in 1.5ml of 5%FCS-
EMEM for 3 days. The medium was replaced with non-
supplemented EMEM and cultured for a further 24h
before experimental conditions were applied. After 24h
under experimental conditions RNA was collected from
the cells using RNeasy mini kit (Qiagen Ltd, Crawley,
UK). Five hundred nanograms of total RNA at a ﬁnal
concentration of 50 or 25ng/ml was aliquoted into RNase-
free thin-walled eppendorf tubes. Equal volumes of
Random Primers (Promega, WI, USA) and 10mM
dNTP (Bioline, London, UK) were mixed together, and
2ml of this mix was added to each of the diluted RNA
samples. After brief vortex mixing and centrifuging for
30s at 13,000rpm, samples were placed in a Peltier
Thermal Cycler-DNA Engine (MJ Research Inc., Reno,
NV), and incubated at 658C for 5min, and then another
5min at 48C. A mixture containing: 40U/mlo f
RNaseOUT Recombinant Ribonuclease inhibitor;
100mM DTT and 5X First Strand Buﬀer (Invitrogen)
was prepared in a ratio of 1:2:4, respectively, and 7mlo f
this mixture was then added to each sample. Samples were
centrifuged for 30s at 13,000rpm before incubation at
258C for 10 minutes in the Peltier Thermal Cycler,
followed by 428C for 2min. One microlitre of
Superscript II (Invitrogen Ltd, Paisley, UK) was added,
and reverse transcription was performed at 428C for
50min and then 708C for 15min. Final cDNA samples
were diluted with sterile double distilled water to a ﬁnal
concentration of 5ng/ml. The QRT-PCR was performed
with an Opticon 2 DNA Engine (MJ Research Inc., Reno,
NV). Primer oligonucleotide sequences speciﬁc for Pax6
were 50-GAATCAGAGAAGACAGGCCA-30 upstream
and 50-GTGTAGGTATCATAACTCCG-30 downstream
and for GAPDH were 50-ACCACAGTCCATGCCATC
AC-30 upstream and 50-TCCACCACCCTGTTGCTGTA-
30 downstream. Level of product was determined by
SYBR green (Finnzymes, Finland) which binds exclu-
sively to double-stranded DNA resulting in a ﬂuorescence
emission proportional to the amount of the product. A
50ml reaction mixture was prepared for each cDNA
sample containing: 50ng cDNA; SYBR green 2x; 2mM
forward and reverse primers (Invitrogen) and double
distilled water to total ﬁnal volume. Serial dilutions of
cDNA known to express the gene of interest were
prepared to permit relative levels between test samples to
be determined. QRT-PCR was performed using
the following program: step 1—initial denaturation at
948C 4min; step 2—denaturation at 948C for 20s; step 3—
annealing at 558C for 30s; step 4—extension at 728C for
20s; step 5—‘cut oﬀ’ for 10s at 808C (GAPDH) or 828C
(Pax6) to denature potential primer dimers, this was then
followed by ﬂuorescent dye measurement. Steps 2–5 were
repeated for 35 cycles. Additional, melting curve analysis
was performed to determine the quality of product.
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The P6CON and human P1 luciferase reporter plasmids
have been described elsewhere (26,27), while P1(iPBS)-
Luc is described below. HEK-293 cells were transiently
transfected with these reporter constructs in combina-
tion with expression plasmids encoding Pax6
(pcDNA3.zPax6.1) and a constitutively activated TGFb
type I receptor (pCMV1-TGFbRI-T204D). Cells were
lysed 48h post-transfection and lysates were assayed for
luciferase activity. FHL124 cells were transfected with
Lipofectamine 2000 (Gibco) in serum-free media. Cells
were incubated in 0.5% FCS-containing media overnight
before stimulation with 5ng/ml TGFb and then assayed
for luciferase activity.
DNA cloning andsequence analysis
The dominant negative paired domain expression
construct PD (pCMV1.Pax6-PD-Flag) was generated as
follows. Site-directed mutagenesis was used to insert an
EcoRI restriction site into the coding sequence of
pCMV1.xPax6-N-GFP downstream of the paired box
using the following primers: 50-GACAAGCTCAG
GATGCTCGAGGGACAAACTGCAACT-30 sense and
50-AGTTGCAGTTTGTCCCTCGAGCATCCTGAGCT
TGTC-30 anti-sense. The paired box sequence was then
excised by EcoRI restriction site, taking advantage of a
pre-existing EcoRI site upstream of the paired box, and
ligated into a pre-prepared expression vector,
pCMV1.Flag.
The luciferase reporter P1(iPBS)-Luc was generated
by site-directed mutagenesis and restriction enzyme
digestion of P1-Luc. First, EcoRI restriction sites were
inserted immediately upstream and downstream of the
putative paired domain-binding site in P1-Luc using the
following primers: 50-GCGAGCGGTGCATTTGAATT
CTGCGGAGTGATTAGT-30 sense and 50-ACTAATC
ACTCCGCAGAATTCAAATGCACCGCTCGC -30
anti-sense for the upstream site, and 50-GGAGTGA
TTAGTGGGTTTGGAATTCGAACCGTGCTCGGCC
TC-30 sense and 50-GAGGCCGAGCACGGTTCGAATT
CCAAACCCACTAATCACTCC-30 anti-sense for the
downstream site. The plasmid was then digested
with EcoRI to excise the intervening sequence before
re-ligation.
All DNA sequence analyses and alignments were
performed using the DNA Star Lasergene software
package. Accession numbers for the human and Xenopus
Pax6 P1 promoter sequences are U63833 and AY048575,
respectively.
Immunoprecipitation andimmunoblotting
HEK-293 cells were transiently transfected with
expression plasmids encoding GFP-tagged Smads
(pCMV1-Smad2-N-GFP, pCMV1-Smad3-N-GFP,
pCMV1-Smad4-C-GFP) in combination with Flag-
tagged Pax6 (p3xFlag-mPax6) and the constitutively
activated TGFb type I receptor. Cells were lysed in
Lysis Buﬀer (50mM HEPES pH7.5, 150mM NaCl, 1mM
EDTA, 1% (v/v) Triton X-100, 10% (v/v) Glycerol)
48h post-transfection and lysates were immunoprecipi-
tated with anti-GFP antibody and protein A-sepharose.
Immunoprecipitates were subjected to immunoblotting
along with a fraction of each lysate for protein expression
levels. For immunoprecipitation of endogenous proteins,
FHL124 cells were serum-starved for 24h before stimula-
tion with 10ng/ml of recombinant TGFb1 for a further
24h. Un-stimulated cells were maintained in serum-free
conditions as a control. Cell lysates were immunoprecip-
itated with anti-Pax6 (H-295, Santa Cruz) antibody and
protein A–sepharose. Immunoprecipitates and cell lysates
were subjected to immunoblotting. Protein A-HRP
conjugate was substituted for secondary antibody to
prevent anti-Pax6 heavy chain from obscuring Pax6 and
Smad3 signals in immunoprecipitates.
GST pull-down assays
GST fusion constructs of Smad1, 2, 3, 4, 5 and 7 or
fragments of Smad3 were expressed in Escherichia coli
and puriﬁed using glutathione-sepharose 4B beads
(Amersham Pharmacia Biotech.). Equal amounts of
GST or GST-Smads bound to glutathione-sepharose
beads were incubated with lysates from HEK-293 cells
transiently transfected with Pax6. Beads were washed ﬁve
times in Wash Buﬀer (20mM HEPES, 150mM NaCl,
0.1% (v/v) Triton X-100, 10% (v/v) Glycerol), and
interacting proteins were detected by immunoblotting.
Expression of GST fusions was conﬁrmed by Coomassie
blue staining. Where appropriate, GST fusions of full-
length Smad3, or fragments of Smad3, were puriﬁed from
E. coli LE392 or E. coli BL21-Star(DE3)pLysS
(Invitrogen) extracts using glutathione-sepharose beads
(Amersham Pharmacia Biotech.). These were then
incubated with pre-cleared Pax6, Pax6HD and
Pax6PD synthesized by in vitro transcription and trans-
lation in the presence of [35S] methionine. Similarly, GST
fusions of Pax6 paired domain or its individual sub-
domains, PAI and RED, were incubated with [35S]
methionine-labelled Smad3 and Smad4. These pull-down
assays were performed exactly asdescribed previously (6).
DNA bindingassays
HEK-293 cells were transfected with expression plasmids
encoding Flag-tagged Pax6 in combination with
HA-tagged Smad3 (pCMV1-Smad3-N-HA) and the con-
stitutively activated TGFb type I receptor. Cells were
lysed 48 hours post-transfection, and lysates
were incubated for 2h with 1mgo f5 0 biotinylated,
double-stranded oligonucleotide corresponding to the
P6CON paired domain-binding sequence using a protocol
described previously (28). DNA–protein complexes
were precipitated with streptavidin–agarose beads for
1h and subjected to immunoblotting. For gel mobility
shift assays, GST fusion proteins were puriﬁed
from E.coli BL21-Star(DE3)pLysS extracts, and binding
of GST-Pax6-PD and GST-Pax6-HD to
32P-labelled
P1 promoter probes performed as described previously
(29). The following PCR primers were
used to generate probes: Full-length P1-F (50-CCCG
GGCTCGGGGGCCCTG-30); Full-length/short P1-R
892 Nucleic Acids Research, 2007, Vol. 35, No. 3(50-GCCGGCGCCCGGCCTCGCCTCC-30); Short
P1-F (50-ATTTGCATGTTGCGGAGTGATTAG-30).
RESULTS
TGFbrepresses endogenous Pax6 expression and
Pax6-dependent promoter activity
Initially we studied the eﬀects of TGFb signalling on Pax6
expression in the human lens FHL124 cell line.
TGFb1 and TGFb2 caused signiﬁcant reductions in
endogenous Pax6 mRNA expression of 34 and 49%,
respectively, within 24h (Figure 1A). While both TGFb
isoforms yielded signiﬁcant repressions of Pax6 expres-
sion, there was no signiﬁcant diﬀerence in the extent of
repression by the two isoforms. These data suggest that
the Smad/TGFb signalling pathway can regulate
transcriptional activity at the Pax6 locus.
Of all Pax6 promoters identiﬁed to date, the human P1
is the best characterized. Its core activity has been
narrowed down to approximately 350bp of sequence
and includes the so-called Exon 1 enhancer (26). Reporter
assays were performed with a Pax6 P1-Luc luciferase
reporter plasmid comprising the minimal 350bp of the
Pax6 P1 promoter. HEK-293 human embryonic kidney
cells were transfected with P1-Luc and co-transfected with
or without a constitutively activated TGFb type
I receptor. Consistent with our analysis of the endogenous
gene, P1 promoter activity dropped to 40% of its basal
rate in the presence of activated receptor (Figure 1B).
Autoregulation by Pax6 appears to be an evolutionary
conserved behaviour of P1 promoters, and has been
demonstrated in reporter assays for human, quail (8,10)
and now Xenopus P1. In our experiments, we found that
overexpression of Pax6 protein resulted in  2.5-fold
induction of basal activity, conﬁrming the autoregulatory
Figure 1. TGFb represses Pax6 expression and autoregulation. (A) TGFb inhibits Pax6 expression in human lens epithelial cells. FHL124 cells were
serum starved for 24 hours and stimulated with 10ng/ml TGFb1 or TGFb2 for a further 24h. Total RNA was extracted and reverse transcribed.
Endogenous Pax6 expression was quantiﬁed by quantitative real-time PCR. Data were normalized with mGAPDH control and represent mean
þ/ SEM (n¼4). (B) Constitutively activated TGFb receptor I inhibits expression and autoregulation of the Pax6 P1 promoter in reporter assays.
HEK-293 cells were transiently transfected with 2mg of P1-Luc in combination with 5mg of caTGFbRI or Pax6. Cells were lysed 48h
post-transfection and luciferase assays were performed. The data represent mean þ/ SEM (n¼9). (C) Constitutively activated TGFb receptor
I inhibits Pax6 protein function in reporter assays. HEK-293 cells were transiently transfected with 2mg of P6CON-Luc in combination with 5mgo f
caTGFbRI or Pax6. Cells were lysed 48h post-transfection and luciferase assays were performed. The data represent mean þ/ SEM (n¼4).
(D) Time-course-dependent repression of P1-Luc and P6CON-Luc in FHL124 cells by TGFb ligand stimulation. FHL124 cells were transfected with
1mg of Pax6-P1-Luc or P6CON-Luc using Lipofectamine 2000, serum-starved overnight, and stimulated with 5ng/ml TGFb for the times
indicated. Cells were lysed and luciferase assays were performed (n¼3).
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Furthermore, co-expression of the activated TGFb type
I receptor, completely blocked this auto-induction reveal-
ing the dominance of TGFb induced repression
(Figure 1B). This eﬀect could not be explained by a
reduction in exogenous Pax6 expression by the activated
TGFb type I receptor based on western blotting of cell
lysates with a speciﬁc Pax6 antibody (Figure 1B; lower
panel). Interestingly, the same pattern of Pax6 autoregula-
tion and TGFb repression was observed for an equivalent
reporter construct derived from the Xenopus P1 promoter
(data not shown).
Given that TGFb repression may be speciﬁcally
targeting Pax6 autoregulation, the potential eﬀects of
TGFb on Pax6 protein function were investigated. If the
repression of P1 were due to impeded protein function,
then other Pax6 responsive promoters might be expected
to exhibit similar behaviours to P1. This issue was
addressed with the synthetic Pax6 responsive promoter
P6CON-Luc, containing 6 repeats of an optimized paired
domain DNA binding sequence (30). Since this is
a synthetic construct containing only Pax6 responsive
elements, any repression by the TGFb pathway must
function independently of promoter speciﬁc cis-regulatory
elements. HEK-293 cells were transfected with P6CON-
Luc in combination with expression constructs encoding
the constitutively activated TGFb type I receptor and
Pax6. Cells were lysed 48h post-transfection, and lysates
assayed for luciferase activity. Pax6 overexpression
resulted in a 5-fold induction of P6CON activity, and
the activated type I receptor exhibited the same dominant
inhibition as with the P1 promoter (Figure 1C). These
data suggest that TGFb represses Pax6 gene expression by
inhibiting Pax6 protein function, and thus autoregulation
of its own promoter.
Next, we examined the eﬀect of TGFb ligand stimula-
tion, rather than overexpressed activated TGFb receptors,
on P1-Luc and P6CON-Luc activity in transfected lens
epithelial FHL124 cells in which Pax6 autoregulation is
likely to play a more physiologically relevant role.
The transcriptional activity of both P1-Luc and P6CON-
Luc show a time-dependent repression reaching around
40% of the unstimulated activity after 21h treatment with
TGFb (Figure 1D).
Pax6bindstoP1andautoregulatespromoteractivitydirectly
Given that the HEK-293 cells are known to express Pax6
endogenously (31), we attempted to determine whether
P1-Luc basal activity included an autoregulatory compo-
nent that might explain its repression by the activated
TGFb receptor. First, the Pax6 paired domain (PD) was
isolated and cloned into an expression construct in an
attempt to create a dominant negative peptide, since
previous studies have reported that truncated Pax6
proteins act in dominant negative fashion (32,33). The
eﬃcacy of the PD peptide in blocking Pax6 protein
function was determined in reporter assays whereby
P6CON-Luc was co-transfected into HEK-293 cells in
combination with PD and full-length Pax6. As shown in
Figure 2A, PD was able to inhibit Pax6 activation of
P6CON-Luc, recapitulating the pattern observed with the
activated TGFb receptor.
Next, the inﬂuence of the dominant negative paired
domain on basal P1-Luc activity was assessed by
co-transfection of HEK-293 cells with P1-Luc with or
without PD, and subsequent reporter assay. The resulting
data showed a 60% inhibition of basal P1-Luc activity in
the presence of the dominant negative PD (Figure 2B),
indicating that this expression includes a signiﬁcant
autoregulatory component. It is therefore likely that the
repression of P1-Luc basal and Pax6-induced activity
may be explained by a single mechanism for the
TGFb-repression of Pax6 autoregulation.
To conﬁrm that Pax6 autoregulates P1-Luc directly, we
attempted to identify a functional Pax6 binding site within
P1. Since human and Xenopus P1 promoters were
observed to behave identically in response to TGFb
receptor activation, the nucleotide sequences of these
promoters were aligned to highlight evolutionary con-
served nucleotides. A second alignment was then per-
formed with the consensus-paired domain binding
sequence P6CON (Figure 2C). Interestingly, P6CON
aligned to a well-conserved region of the human and
Xenopus P1 promoters, just downstream of the TATA box
and transcription initiation site. P6CON aligned to human
and Xenopus sequences with identities of 74 and 68% to
the consensus paired domain-binding site, respectively.
Site-directed mutagenesis was then used to determine
the functional signiﬁcance of this putative paired domain-
binding site (PBS). EcoRI restriction sites were inserted
immediately upstream and downstream of this sequence in
P1-Luc. The intervening putative binding site was then
excised by EcoRI restriction enzyme digestion before P1-
Luc was re-ligated, yielding P1(iPBS)-Luc. The ability of
Pax6 to autoregulate P1(iPBS)-Luc was assessed follow-
ing transfection of HEK-293 cells with the mutated
reporter in combination with Pax6. Figure 2D shows
that exogenous Pax6 is unable to autoregulate the P1
promoter following deletion of the putative paired domain
binding site. These data suggest that Pax6 autoregulation
of P1-Luc is direct and mediated through this novel paired
domain-binding site. The direct interaction of Pax6 with
the region of the P1 promoter encompassing this novel
interaction site was then assessed by gel mobility shift
assay. GST-Pax6-PD proteins comprising the paired
domain bind to both the full-length P1 promoter and
also very weakly, but signiﬁcantly, to a shorter P1 probe
that includes the putative paired domain-binding site
(Figure 2E). Interestingly, GST-Pax6-HD proteins com-
prising the homeodomain are also bound to both the full-
length and short P1 probes (Figure 2E). Equivalent gel
shifted bands were not seen using GST proteins as a
control (data not shown). The sites of homeodomain
interaction with DNA are represented normally by a
palindromic sequence comprising two TAAT half-sites
separated by a conserved linker (5). There are no such
consensus sites in the P1 promoter, and the signiﬁcance of
the homeodomain binding to P1 in the context of Pax6
autoregulation is not clear at present. Additionally, we
cannot exclude the possibility that Pax6 interacts also with
other regions in P1 that may explain the appearance of
894 Nucleic Acids Research, 2007, Vol. 35, No. 3Figure 2. Pax6 paired domain mediates direct autoregulation of promoter P1. (A) An isolated Pax6 paired domain (PD) inhibits the function of full-
length Pax6 in dominant negative manner. HEK-293 cells were transiently transfected with 2mg of P6CON-Luc in combination with 5mg of Pax6
or PD. Cells were lysed 48h post-transfection and luciferase assays were performed. The data represent mean þ/ SEM (n¼3). (B) Dominant
negative paired domain (PD) inhibits the basal activity of promoter P1 indicating an autoregulatory component. HEK-293 cells were transiently
transfected with 2mg of P1-Luc in combination with 5mg of PD. Cells were lysed 48h post-transfection and luciferase assays were performed.
The data represent mean þ/ SEM (n¼5). (C) Alignment of the human and Xenopus Pax6 P1 promoters reveals an evolutionary conserved putative
paired domain-binding site. Sequences of the human and Xenopus Pax6 P1 promoters were aligned in the region corresponding to the reporter
construct P1-Luc. This alignment was then aligned to the consensus-paired domain binding sequence, P6CON, which is boxed
(Note: this is the reverse-complement P6CON sequence as the putative binding site is encoded 50 to 30 on the opposite strand). A broken arrow
indicates orientation of the P6CON consensus. Nucleotides matching the majority sequence are shaded in grey, while the TATA and CCAAT boxes
are shaded in black. Bold letters indicate the location of PCR primers used to generate DNA probes for gel-shift assays, and solid lines indicate
primer orientation. Human transcription start site is indicated as þ1. (D) Deletion of a putative paired domain binding site in promoter
P1 (P1(iPBS)-Luc) disrupts Pax6 autoregulation. HEK-293 cells were transiently transfected with 2mg of P1(iPBS)-Luc in combination with
5mg of Pax6. Cells were lysed 48h post-transfection and luciferase assays were performed. The data represent mean þ/ SEM (n¼5). (E)
Gel mobility shift assay of GST-Pax6-PD and GST-Pax6-HD binding to the P1 promoter. Equal amounts of GST-Pax6-PD and GST-Pax6-HD were
used as described in the materials and methods. Probe 1 was ampliﬁed using the PCR primers FL-P1-F and FL-P1-R, and Probe 2 using S-P1-F and
FL-P1-R as indicated in the P1 sequence shown in Figure 2C. The actual primer sequences used here are provided in the materials and methods. The
migration of the major shifted bands is indicated as (
 ).
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Most importantly, the data presented in Figure 2 show
that the Pax6 paired domain can bind to the P1 promoter
in a region that includes a predicted paired domain-
binding site, the deletion of which completely abrogates
the autoregulation of P1 by Pax6.
Pax6 interacts withSmadproteins
Upon ligand activation of the TGFb receptor complex,
the receptor activated Smad proteins (Smad2 and 3),
together with the common mediator Smad (Smad4),
translocate to the nucleus where they exert their inﬂuence
on gene expression. To examine whether Smads are then
able to interact with Pax6 once inside the nucleus, GST
pull-down experiments were performed using a panel of
GST-Smad proteins representing R-Smads, Co-Smad and
I-Smads (R-Smad1, 2, 3, 5; Co-Smad4; I-Smad7), together
with lysates from cells expressing Flag-tagged Pax6. As
shown in Figure 3A, there are clear in vitro interactions
between Pax6 and GST-Smad1, 3, 4 and 5, but not GST-
Smad2 or 7. Since I-Smads are known to be the least
structurally conserved Smad proteins, and given their role
in the TGFb pathway, an interaction between Smad7 and
Pax6 was not expected. However, it appears from this
assay that Smad2 is the only R-Smad that does not
interact with Pax6. The failure to observe any interaction
between these proteins might be explained by the
unique structural features of Smad2, since the major
isoform used in this assay contains an insert within its
MH1 domain which disrupts that domain’s ability to bind
DNA (34).
Co-immunoprecipitation assays were performed to
screen for in vivo interactions between Smad proteins
and Pax6. HEK-293 cells were transfected with expression
constructs encoding Flag-tagged Pax6 in combination
with constitutively activated TGFb type I receptor and
GFP-tagged Smad2, 3 or 4, and cell lysates were
immunoprecipitated with anti-Flag. None of the Smad
proteins investigated were observed to interact with Pax6
in the absence of constitutively activated TGFb receptor I
(Figure 3B). Following TGFb pathway activation
however, Smad3 but not Smad2 or 4 was seen to interact
with Pax6 (Figure 3B). These data serve to validate the
interaction of Smad3, and non-interaction of Smad2 with
Pax6, while invalidating the Smad4 interaction that was
observed only in vitro. Most importantly these ﬁndings
suggest that Smad3 interaction with Pax6 is dependent on
TGFb pathway activation in vivo.
We next sought to conﬁrm that Pax6 interacts with
Smad3 endogenously in FHL124 lens epithelial cells
following stimulation with TGFb ligand. Cells were
serum-starved for 24h and either stimulated with 10ng/
ml TGFb1 for 8h, or maintained in serum-free conditions
for the same period. The cells were then lysed and lysates
immunoprecipitated with anti-Pax6. Figure 3C demon-
strates the endogenous interaction of Pax6 and Smad3
following TGFb stimulation of lens epithelial cells, and
immunoprecipitations with control immunoglobulins con-
ﬁrm that this interaction is speciﬁc. No detectable Smad2
was found in Pax6 immunoprecipitates even though
FHL124 cells express reasonably high levels of Smad2
(data not shown). We have not been able to identify the
presence of Smad4 in Smad3/Pax6 complexes, although
the overall detectable levels of Smad4 are extremely low in
FHL124 cells and the occurrence of this complex in vivo
cannot be excluded. Additionally, we have not detected
any DNA using ethidium bromide staining in Smad3/Pax6
complexes (data not shown).
Figure 3. Interaction of Smads with Pax6. (A) Pax6 interacts with
Smad1, 3, 4 and 5 in vitro. Lysates were prepared from HEK-293 cells
that had been transiently transfected with p3xFlag-Pax6. These were
then incubated with GST-Smad proteins bound onto glutathione beads.
Following extensive washing, Pax6 associated with the Smad-GSTs was
identiﬁed by elution of beads with SDS-Laemmli buﬀer, separation by
10% SDS-PAGE, and western blotting using a speciﬁc Pax6 antibody
(Santa Cruz, cat. No. SC-20). GST alone was used as a control. The
presence of the GST proteins was conﬁrmed by staining gels with
Coomassie Blue (C/Blue). (B) Pax6 interacts with Smad3 in the
presence of constitutively activated TGFb receptor I in vivo. HEK-293
cells were transfected as indicated. Pax6-Flag was immunoprecipitated
with anti-FLAG antibody. Samples were separated by 10% SDS-
PAGE and immunoblotted with anti-GFP antibody. (C) Pax6 and
Smad3 interact endogenously in response to TGFb stimulation of
human lens epithelial cells.
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In order to investigate the speciﬁc domains involved in the
observed Smad3/Pax6 interaction, further GST pull-down
assays were performed using a panel of Smad3 protein
fragments (Figure 4A), and lysates from cells expressing
Flag-tagged Pax6. Pax6 clearly interacts with the isolated
MH1 domain of Smad3 and a Smad3 fragment lacking the
MH2 domain but retaining the linker region (Figure 4A).
Moreover, no Pax6 interaction was observed with either
the isolated linker region, or a Smad3 fragment lacking the
MH1 domain. A similar analysis was performed in order
to verify those data and determine the speciﬁc Pax6
domains required for Smad3 interaction. GST pull-down
assays were performed using a panel of Smad3–GST
protein fragments and a series of in vitro translated [
35S]-
methionine Pax6 constructs, either whole or possessing
diﬀerent Pax6 sub-domain deletions (Figure 4B). GST
fusions with the Smad3 MH1 domain, but not the MH2
domain, were found to bind strongly with Pax6 constructs
that include the paired domain and weakly to those
including only the homeodomain (Figure 4B). GST
fusions lacking the MH2 domain interacted more strongly
than those containing it, suggesting intra-molecular
regulation of the interaction within Smad3. We also
found that the MH1 domain of Smad3 binds to the RED
sub-region of the paired domain in Pax6 (Figure 4C). It is
interesting to note that the strongest interaction is
observed between isolated paired domain and MH1
domain. Intra-molecular regulation is known to occur
between the paired and homeodomain of Pax6 (6,35), and
between MH1 and MH2 domains of R-Smads (36). Such
regulation is known to inhibit inter-molecular domain
interactions between R-Smads, and thus formation of
active Smad complexes in the absence of TGFb receptor
activation. It is possible therefore that intra-molecular
inhibition within Smad3 may contribute to the TGFb-
dependence of Pax6 association.
Smad3prevents Pax6 paired domain frombinding DNA
The interaction of Smad3 with the Pax6 paired domain
also suggests an alternative mechanism for the repression
of Pax6 function by the TGFb signalling pathway. Since
the paired domain is the dominant DNA binding domain
of Pax6, it is possible that its association with Smad3 may
inhibit Pax6 DNA binding, and so abrogate transactiva-
tion. DNA adsorption assays were performed to deter-
mine the potential inﬂuence of Smad3 over Pax6 DNA
binding. We used an established DNA adsorption proto-
col (28), and the assay brieﬂy consisted of binding a
biotinylated P6CON aptamer with overexpressed Pax6
protein in cell lysates (Figure 5A). HEK-293 cells
were transfected with expression constructs encoding
Flag-tagged Pax6, HA-tagged Smad3 and constitutively
activated TGFb type I receptor. Streptavidin–biotin pull-
down in the absence of P6CON aptamer yielded no Pax6
protein, while addition of aptamer resulted in eﬃcient
pull-down of Pax6 due to DNA binding (Figure 5B).
When Pax6 was co-expressed with Smad3, a signiﬁcant
reduction was observed in the level of Pax6 DNA
binding (Figure 5B). Moreover, Smad3 when expressed
alone failed to co-precipitate with the P6CON (data not
shown), suggesting that Pax6 paired-domain interactions
with Smad3 and DNA are mutually exclusive.
DISCUSSION
This study establishes that the TGFb pathway represses
Pax6 expression by targeting the autoregulation of the
Pax6 P1 promoter. Signiﬁcantly, both P1-Luc and
P6CON-Luc, whose activities are induced through the
operation of Pax6 paired domain-binding elements, are
identically repressed by TGFb signalling, strongly sug-
gesting that TGFb targets Pax6 protein function rather
than speciﬁc TGFb response elements in either of the two
promoters, since there are no Smad binding elements
encoded in P6CON-Luc. We have not seen any signiﬁcant
eﬀect of Pax6 overexpression on the activation of a Smad-
dependent CAGA12-luciferase reporter by TGFb (data
not shown). Therefore, it is unlikely that Pax6/Smads can
have inverse roles via Smad binding elements, although
the structural basis for these diﬀerences are not clear at
present.
Importantly, we have identiﬁed a novel paired domain-
binding site in the P1 promoter, and shown that deletion
of this sequence completely abrogates Pax6-stimulated P1
promoter activity. The basal activity of this mutant P1
promoter is still however partially repressed by TGFb
(data not shown), and it remains possible that the basal
and Pax6-stimulated regulation of the P1 promoter will
have additional layers of complexity that remain to be
explored. Indeed, we have found Pax6 homeodomain
interactions with the P1 promoter in vitro, for example,
and other studies have deﬁned a number of transcription
factor binding sites that also have the potential to
inﬂuence basal as well Pax6/Smad-regulated activity
(26). Subsequently, we have explored the mechanism of
Pax6 repression by TGFb signalling and shown that it is
due to speciﬁc Pax6/Smad protein interactions (Figure 6).
Pax6 was found to interact with activated Smad3
following stimulation of TGFb receptors with TGFb
ligand, or overexpression of a constitutively active
TGFb type I receptor. Furthermore, in vitro analyses of
speciﬁc protein domains demonstrated the involvement of
Smad3 MH1 domain and Pax6 paired domain in Pax6/
Smad3 association. Using a simple DNA adsorption
assay, we have also shown that Smad3 can release Pax6
from the P6CON consensus DNA-binding site. In vitro
GST pull-down data implied an interaction between
Pax6 and Smad4, which could not be validated by
co-immunoprecipitation experiments, while Pax6 inter-
actions with Smad1 and 5 of the BMP pathway are yet to
be veriﬁed.
TGFb signalling appears to be necessary for Pax6/
Smad3 interaction, and this dependence may arise from
two mechanistic components. First, as a transcription
factor Pax6 is a predominantly nuclear protein, so its in
vivo association with Smad3 would require nuclear
shuttling of the R-Smad and therefore TGFb signalling.
Second, in vitro analysis indicated a possible role for the
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MH1 domain. Since the auto-inhibition between MH1
and MH2 domains is alleviated following C-terminal
phosphorylation by an activated type I receptor (36), it is
possible that TGFb signalling also regulates Smad3
aﬃnity for Pax6. While a small amount of endogenous
Pax6/Smad3 interaction was observed in FHL124 cells in
the absence of exogenous TGFb ligand, it is possible that
Figure 4. The MH1 domain of Smad3 interacts primarily with the paired domain of Pax6. (A) Lysates were prepared from HEK-293 cells that had
been transiently transfected with pcDNA3-Pax6. These were then incubated with GST-Smad truncated proteins as indicated in the left-hand
schematic diagram and, following extensive washing, associated proteins were identiﬁed by elution of beads with SDS-Laemmli buﬀer, separation by
10% SDS-PAGE, and western blotting using a speciﬁc Pax6 antibody. The presence of the GST proteins was conﬁrmed by staining gels with
Coomassie Blue (C/Blue). (B) Pax6 constructs used for in vitro translation are shown in the left-hand panel. GST pull-down assays were performed
with full-length Smad3 and diﬀerent domains of Smad3 fused to GST and immobilized on glutathione-agarose beads and Pax6, Pax6HD and
Pax6PD produced by in vitro transcription and translation in the presence of [
35S]-methionine. Ten-microliter portions of the in vitro translation
reactions were preincubated with GST immobilized on glutathione-agarose beads before incubation with the GST fusion proteins. The GST beads,
GST-Pax6HD beads and GST-Pax6PD beads were washed several times before they were boiled and run on a 10% SDS–polyacrylamide gel.
Two microlitres of the in vitro translated proteins were run on the same gel to visualize the signal from 20% of the input as shown in the middle
panel. (C) GST-Pax6 sub-paired domain constructs are shown in the left-hand schematic panel. The right panel shows the results of GST pull-down
assays with the paired domain (PD) of Pax6 and the two sub-domains, PAI and RED fused to GST and immobilized on glutathione–agarose beads
and Smad3 or Smad4 produced by in vitro transcription and translation in the presence of [
35S]-methionine. Samples were prepared and separated as
described above in Section B.
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ling. We have not been able to see a signiﬁcant reduction
in this basal Pax6/Smad3 association in the presence of a
speciﬁc type I TGFb receptor inhibitor SB431542,
however, FHL124 cells may express other functional
type I TGFb receptor isoforms that lack sensitivity to
these inhibitors (37).
While early investigations of Smad-mediated transcrip-
tional regulation largely concerned mechanisms of activa-
tion, an increasing number of reports are emerging which
describe mechanisms of repression. Generally speaking,
such mechanisms may be divided into those involving
Smad/DNA binding and those that are independent of
such associations. A recent study of the myogenic factor
MEF2 provides an example of a Smad-mediated tran-
scriptional repression independent of direct Smad/DNA
binding. Smad3 MH2 domain was reported to interact
with MEF2C while the latter is bound to its target DNA
sequence (28). At the myogenin promoter, the physical
association of Smad3 with MEF2C disrupts the transcrip-
tion factor’s recruitment of the coactivator GRIP-1,
resulting in transcriptional repression. Another example
of a Smad/DNA independent mechanism is that of
Smad1/Hoxc-8 and the osteopontin promoter. BMP
stimulation leads to the nuclear accumulation of Smad1
and its subsequent interaction with Hoxc-8 (38,39).
However, rather than regulating co-factor recruitment,
the Smad1/Hoxc-8 association disrupts Hoxc-8/DNA
binding at target sequences in the osteopontin promoter.
BMP stimulation of the Smad1/Hoxc-8 interaction results
in the activation of the osteopontin promoter, since Hoxc-
8 acts as a transcriptional repressor. Although this
constitutes an activation of gene expression, this result is
achieved through the targeted inhibition of transcription
factor/DNA binding. Indeed, the basic mechanism closely
resembles that of Smad3/Pax6 transcriptional repression
reported here.
While Smad proteins have been reported to interact
with many diﬀerent homeodomain transcription factors,
this is only the second study to demonstrate an interaction
with a paired box transcription factor, and the ﬁrst to do
so endogenously. The only previous study concerned the
class II paired box gene Pax8, and its interaction with
Smad3 (40). Pax8/Smad3 interaction was demonstrated in
vitro, as was its inhibitory eﬀect on Pax8 DNA binding,
however no endogenous interaction was reported.
Another notable distinction between the current and
previous studies is the demonstrated inﬂuence of TGFb/
Smad signalling on Pax6 autoregulation. This ﬁnding
resulted from the analysis of Pax6 promoters, whereas
Pax8 function was assayed only in relation to a down-
stream promoter. The current study raises at least one
potential implication for Pax8 regulation since, in addition
to Pax8 functional repression by TGFb, there was a
corresponding repression of Pax8 expression that could
not be explained (40). Given that inhibition of Pax6
function leads to a repression of its autoregulation and
thus expression, it is possible the same mechanism holds
for Pax8. Although no other evidence exists that supports
a case for Pax8 autoregulation, the TGFb/Smad inhibi-
tion of Pax6 and Pax8, expression and function, are
potentially equivalent and may represent a more general
paradigm for the regulation of paired box transcription
factors by the TGFb superfamily. While Pax8 encodes a
partial homeodomain, like all Pax genes it encodes a full-
length paired domain. Moreover, Pax8, Pax5 and Pax2 all
share a consensus paired domain-binding sequence which
is closely related to that of Pax6 (27). Interestingly, other
Figure 5. Smad3 prevents Pax6 paired domain from binding DNA.
(A) Schematic representation of the experimental protocol for the
DNA absorption assay together with the sequence of the biotinylated
P6CON aptamer. (B) Biotinylated double-stranded P6CON oligonu-
cleotide immobilized on streptavidin beads was incubated with lysates
of HEK-293 cells transfected with the indicated expression plasmids.
Pax6 bound to P6CON was analysed by immunoblotting using anti-
Flag antibodies. The lower panels show the expression levels of
Pax6-Flag and Smad3-HA proteins as analysed in immunoblots of the
cell lysates.
Figure 6. Summary of the mechanism for the repression of Pax6
function by Smads. Our results show that TGFb represses Pax6
promoter activity by inducing the nuclear translocation of Smad3.
(A) Once in the nucleus, Smad3 interacts with the RED sub-domain
of the paired domain in Pax6 and releases Pax6 from its DNA binding
site. (B) Thus, the Smad/TGFb signalling pathway turns oﬀ Pax6
expression by preventing it from autoregulating its own promoter.
Nucleic Acids Research, 2007, Vol. 35,No. 3 899reports describe the inhibition of Pax gene expression by
members of the TGFb superfamily. Pax1 has a role in
patterning the paraxial mesoderm, which forms the
somites. BMP2 and 4 inhibit the expression of Pax1 in
this tissue while the BMP antagonist noggin is required to
abrogate this eﬀect during normal development (41). Pax2
functions in renal tubule cells, where its expression may be
inhibited by TGFb1, although this repression is correlated
with diminished mRNA stability (42). Pax3 and Pax7 are
both involved in the development of skeletal muscle from
the somites. Exposure of somites to ActivinA results in a
loss of Pax3 expression while Pax7 is apparently
unaﬀected (43). Since Pax3 and Pax7 are both assigned
to class II of the paired box gene family, based partly on
protein sequence homology (1), their diﬀerential response
to the same TGFb superfamily signal may not correspond
to any gross structural divergence.
A dynamic change in Pax6 expression also underpins
lens progenitor cell terminal diﬀerentiation, and mice
devoid of Pax6 expression fail to form a lens (9). In the
adult lens, Pax6 is required for maintenance of the lens
epithelium (44), overexpression of Pax6 has been shown to
suppress lens ﬁbre diﬀerentiation by inhibiting the betaB1
crystallin promoter (45), and loss of Pax6 during
diﬀerentiation leads to the expression of this lens ﬁbre
diﬀerentiation marker (46). A reduction in Pax6 expres-
sion has also been suggested to play a key role in the
formation of anterior sub-capsular cataract, a condition
which is also strongly associated with TGFb (47).
Therefore, TGFb signalling could lower Pax6 expression
and at the same time drive epithelial-mesenchymal
transition to provide an important mechanism contribut-
ing to lens opaciﬁcation and cataract formation.
In summary, this study contributes to our under-
standing of a new paradigm that identiﬁes novel molecular
connections linking Pax6 and the TGFb signalling path-
way, two cellular systems that are essential for normal
tissue growth and diﬀerentiation, and also play pivotal
roles in human disease. It is likely that the ﬁne-tuning
of the Pax6-P1 promoter in vivo is due to complex layers of
both temporal and spatial regulation by multiple signal-
ling pathways. Future work will also be needed to fully
understand the roles of BMP-regulated R-Smads in the
control of Pax6 expression and the general applicability of
TGFb superfamily members in coordinating the expres-
sion of other Pax family members.
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